|
Match
|
Document |
Document Title |
|
|
8183224 |
Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's...
|
|
|
8183226 |
Myocardial perfusion imaging method
The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising...
|
|
|
8183225 |
Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a...
|
|
|
8178509 |
Method to treat sickle cell disease
The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an A2A adenosine...
|
|
|
8173618 |
Formulations for reducing neuronal degeneration
Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E,...
|
|
|
8173620 |
BHQ-caged nucleotide probes photolysable by two-photon excitation
The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by...
|
|
|
8158604 |
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
|
|
|
8148348 |
Method of stabilizing S-adenosyl-L-methionine and stabilized composition
Provided are a process for producing a S-adenosyl-L-methionine-containing composition which is very excellent in a stability by adding at least ascorbic acids or salts thereof to a composition...
|
|
|
8133879 |
Myocardial perfusion imaging methods and compositions
The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these...
|
|
|
8133880 |
Purine derivatives and methods of use thereof
The invention relates to Purine Derivatives having the formula; The invention also relates to pharmaceutical compositions comprising an effective amount of the Purine Derivative; and methods for...
|
|
|
8129357 |
Method of making and using an adenosine analogue
This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such...
|
|
|
8119614 |
Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This...
|
|
|
8106029 |
Use of A2A adenosine receptor agonists
Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A2A receptor agonists, in particular...
|
|
|
8097595 |
Modulation of telomere length in telomerase positive cells and cancer therapy
Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention...
|
|
|
8093226 |
Cytostatic 7-deazapurine nucleosides
The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and...
|
|
|
8088752 |
Methods for metabolic modulation
Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine...
|
|
|
8080554 |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also...
|
|
|
8076311 |
Compositions and methods for modulating the immune system
The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides...
|
|
|
8071565 |
Purine derivatives as a2a agonists
Compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating...
|
|
|
8071566 |
Methods of coronary imaging
The present invention provides methods of myocardial perfusion imaging and increasing coronary blood flow of a mammal that are accomplished by administering doses of a compound that is a selective...
|
|
|
8063024 |
Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance
The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.
|
|
|
8058259 |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-pur
in-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions...
|
|
|
8034802 |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention...
|
|
|
8030293 |
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such...
|
|
|
8030294 |
Compounds for the treatment of psychiatric or substance abuse disorders
The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or...
|
|
|
7994143 |
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a...
|
|
|
7989430 |
Antibacterial agents
The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and t...
|
|
|
7989431 |
2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
|
|
|
7985740 |
Purine derivatives as agonists of the adenosine A2A receptor
The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.
|
|
|
7977343 |
Adenine derivatives
Novel adenine derivatives of the formula (I), in which R1, R2, R3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the...
|
|
|
7959944 |
S-adenosyl-L-methionine for regulating behavioral disorders in pets
The present invention relates to the use of S-adenosyl-L-methionine or its salts for preparing a composition for the regulation of behavioral problems in pets.
|
|
|
7939509 |
Partial and full agonists of A1 adenosine receptors
Disclosed are novel compounds a compound of Formula I that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes,...
|
|
|
7915232 |
4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication
The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which...
|
|
|
7888329 |
Substituted aryl piperidinylalkynyladenosines as A2AR agonists
A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).
|
|
|
7888328 |
Oral formulations of cladribine
Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.
|
|
|
7875595 |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
|
|
|
7867983 |
Methods to protect skeletal muscle against injury
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new...
|
|
|
7863253 |
Purine Derivatives and methods of use thereof
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a...
|
|
|
7860552 |
CNS assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
In general, the invention features methods for identifying therapeutic interventions for functional illnesses, e.g., neuropathic pain or depression, and methods for identifying markers for...
|
|
|
7851456 |
P2Y6 receptor agonists for treating lung diseases
This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the...
|
|
|
7846912 |
Deuterium-enriched nelarabine
The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
7842672 |
Phosphonate inhibitors of HCV
A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and...
|
|
|
7825102 |
Treatment of dry eye conditions
The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3 adenosine receptor (A3AR) agonist, the amount...
|
|
|
7825096 |
O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or ...
|
|
|
7812000 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7795236 |
Purine nucleoside derivative modified in 8-position and medical use thereof
The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside...
|
|
|
7790698 |
Use of adenosine receptor agonists in therapy
Compounds of the class of adenosines, represented by structural formula I, wherein R is C1-4 alkoxy, and X is H or OH, are useful in a method of preventing, treating, or ameliorating various...
|
|
|
7792576 |
Method of treatment for central nervous system injury
Injuries to the central nervous system, particularly spinal cord injuries, are treated by administering a purine nucleoside or analog to the patient and, optionally, electrically stimulating the...
|
|
|
7772206 |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate,...
|
|
|
7772198 |
CFTR channel modulators
The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a...
|